Citius Pharmaceuticals, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated August 8, 2017, announces the closing of a previously announced underwritten public offering by Citius Pharmaceuticals, Inc., a Nevada corporation.
Key Financial Metrics
The filing details a capital raise event rather than operational financial results. Key figures include:
- Gross Proceeds: Approximately $6,800,000 (before underwriting discounts, commissions, and offering expenses).
- Shares Sold: 1,648,484 shares of Common Stock.
- Warrants Issued: Warrants to purchase 1,648,484 shares of Common Stock, plus an additional 247,272 warrants from the partial exercise of the over-allotment option.
- Offering Price: $4.125 per share (combined price for stock and warrants).
- Warrant Terms: Exercise price of $4.125, exercisable immediately, expiring five years from issuance.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a transaction report, not a periodic financial statement.
Material Changes
The primary material change is the increase in the company's capital base and the expansion of its outstanding share count and warrant obligations resulting from the closing of the public offering on August 8, 2017.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on future operations, or a discussion of risks and contingencies beyond the standard disclosure of the offering terms. The offering was conducted pursuant to a Registration Statement on Form S-1 (File No. 333-217956) declared effective on August 2, 2017.
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting discounts and offering expenses.
- Confirm the total number of outstanding shares and warrants post-offering.
- Review the attached Press Release (Exhibit 99.1) for details on the intended use of proceeds.
- Check subsequent filings for the impact of this dilution on earnings per share.